Wyeth and Solvay Form Neuroscience Collaboration
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 47 (Table of Contents)
Published: 4 May-2004
DOI: 10.3833/pdr.v2004.i47.809 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Wyeth pharmaceuticals and Solvay Pharmaceuticals entered into an agreement to co-develop and co-commercialize four neurological compounds including Solvay’s bifeprunox, which is in phase III clinical trials for treating schizophrenia and other psychotic disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS